Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026.

On December 19, Gilead Sciences, Inc. (NASDAQ:GILD) announced an agreement with the US government aimed at lowering drug costs for Americans. The move reinforces the company’s long-standing focus on US-based innovation, affordability, and global health leadership.

Under the three-year agreement, Gilead agreed to all requests by President Trump to adopt a new pricing strategy that prioritizes American patients. The goal is to ensure the US no longer carries a disproportionate share of global healthcare costs. The agreement also supports America’s role in global health and biomedical innovation. It builds on Gilead Sciences, Inc. (NASDAQ:GILD)’s recently announced partnership with the US Department of State to provide its breakthrough HIV prevention medicine, lenacapavir, at no profit to up to two million people in the countries most affected by the disease over the next three years.

Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences, made the following statement:

“This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare. The progress toward expanding access and increasing investment in U.S. innovation will meaningfully contribute to America’s health and economic priorities. Gilead Sciences will continue to work with the Administration in service of these priorities for the benefit of generations to come.”

Alongside these efforts, Gilead Sciences, Inc. (NASDAQ:GILD) recently said it plans to invest $32 billion in US-based manufacturing, research and development, and infrastructure over the next five years. The company expects this investment to generate $43 billion in national economic value and create more than 3,000 direct and indirect jobs.

Gilead Sciences, Inc. (NASDAQ:GILD) is a major biopharmaceutical company that researches, develops, and sells innovative medicines, with a focus on treating life-threatening diseases.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Cash-Rich Stocks to Buy Now and 15 Global Dividend Stocks to Diversify Your Portfolio.

Disclosure: None.